PL9643

Palatin CEO claims ‘a positive study on its face,’ despite dry eye drug's primary endpoint miss
Fierce Biotech
Wed, 02/28/24 - 10:49 am
Palatin Technologies
dry eye disease
PL9643
clinical trials